CORCEPT THERAPEUTICS INC Financing Receivable, Allowance for Credit Loss, Writeoff
CORCEPT THERAPEUTICS INC (CORT) reported Financing Receivable, Allowance for Credit Loss, Writeoff of $0 for the 9-month period ending 2014-09-30, per its 10-Q filed 2014-11-07.
Discontinued › Notes › and Others
us-gaap:FinancingReceivableAllowanceForCreditLossesWriteOffs · last filed 2014-11-07
- CORCEPT THERAPEUTICS INC financing receivable, allowance for credit loss, writeoff for the quarter ending 2014-09-30 was $0.00.
- CORCEPT THERAPEUTICS INC financing receivable, allowance for credit loss, writeoff for the quarter ending 2014-06-30 was $0.00.
- CORCEPT THERAPEUTICS INC financing receivable, allowance for credit loss, writeoff for the quarter ending 2014-03-31 was $0.00.
| Period end | Financing Receivable, Allowance for Credit Loss, Writeoff 3 month | Financing Receivable, Allowance for Credit Loss, Writeoff 6 month | Financing Receivable, Allowance for Credit Loss, Writeoff 9 month |
|---|---|---|---|
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-07 | $0.00 derived: sum of 2 quarters · filed 2014-11-07 | $0.00 10-Q · filed 2014-11-07 |
| 2014-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-08 | $0.00 10-Q · filed 2014-08-08 | |
| 2014-03-31 | $0.00 10-Q · filed 2014-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |